Misight presented at BCLA 2017

with 1 Comment

Three-Year Study Indicates Pioneering Contact Lens Therapy Effective in Slowing Myopia Progression in Children by 59%

CooperVision reported three-year data from its Clinical Evaluation of a Dual-Focus Myopia Control 1-Day Soft Contact Lens Study during the British Contact Lens Association (BCLA) Clinical Conference and Exhibition in Liverpool last week, which showed that the innovative therapy substantially slows myopia progression and eye elongation as measured by refractive error and axial length.

The data also illustrates high satisfaction and acceptance of contact lens wear from children and their parents, rapidly overcoming initial parental apprehension

In a featured podium session, CooperVision’s Senior Manager of Clinical Research, Paul Chamberlain, reviewed three-year results from the clinical trial assessing a specially-designed, dual-focus myopia control 1-day soft contact lens in reducing the rate of progression of juvenile-onset myopia. The prospective, multi-centre, double-masked, randomised three year study enrolled 144 myopic children aged 8-12 years from Singapore, Canada, England, and Portugal.

Three-year findings indicated that use of the dual-focus contact lens — which has alternating visual correction and treatment zones — was effective in slowing myopia progression: 59% as measured by mean cycloplegic spherical equivalent (SE) and 52% as measured by mean axial elongation of the eye when compared to the children in the control group wearing a single vision 1-day contact lens.

No other prospective randomised controlled study has shown data for such a high degree of continued efficacy in myopia management over three years.

The prevalence of myopia is projected to increase from approximately two billion people worldwide in 2010 to almost five billion people in 20501, bringing with it both short  and long-term health challenges.
"Myopia's growth has been dizzying and now affects the vast majority of young adults in some countries, especially in East Asia," said Arthur Back, Chief Technology Officer for CooperVision and a leading voice on myopia management. "Not only does it create blurred vision, but also increases the likelihood of conditions later in life such as glaucoma, cataract, retinal detachment and myopic maculopathy if not addressed”.

"Early intervention by parents, in partnership with eye care professionals, is essential for the short- and long-term health and wellbeing of their children. The CooperVision MiSight® dual-focus 1-day lens used in this study provides a new, effective and repeatable approach."

Ensuring that children wear and are happy with the lens is of critical importance to the therapy's effectiveness. Three-year results indicated that the dual focus lens was well accepted by children and did not affect their daily activities such as school work, reading, playing outside and computer use when compared to the control group2. Children in both the test and control groups had a higher satisfaction with contact lenses over spectacles.
Parents of study participants also gave a very positive response, noting their children could mostly manage their lens wear independently. Prior to dispensing contact lenses, less than half of the parents were extremely at ease with their child wearing contact lenses, but this increased significantly to 79% after just one month and remained high through to the three-year mark. After their children had worn MiSight® 1 day contact lenses for three years, almost 9 out of 10 parents rated their children 'extremely happy' with the overall experience of wearing contact lenses3.


1) Holden et al, Ophthalmology 2016.
2) From one-week through three-year visits.
3) Children ages 8-15.


Published with permission of McDougall Communications. Original published at  www.prnewswire.com

Information contained on this page is provided by an independent third-party content provider. Myopiacare and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact us.

One Response

  1. […] MiSight 1 day ist seit 2008 für das Myopie Management zugelassen, und die Drei-Jahres-Studien-Ergebnisse sprechen für […]

Leave a Reply

Your email address will not be published. Required fields are marked *


This site uses Akismet to reduce spam. Learn how your comment data is processed.

myopia.care - the web application for myopia control